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Cancer is a major cause of morbidity and mortality in the Scottish
population (Information & Statistics Division, 1998). In recent
years, there has been rising public and political concern about
perceived variation in the quality of care for patients with cancer in
the UK. Although there are difficulties in interpretation, the results
of the EUROCARE study suggest that the survival prospects for
patients with cancer in the UK may be less favourable than those
reported by some other European countries (Berrino et al, 1995).
A number of recently published studies on historical cohorts of
patients with cancer in Scotland have reported variations in
outcomes apparently related to patterns of care (McArdle and
Hole, 1991, 1996; Junor et al, 1994; Gillis and Hole, 1996).
FORMATION OF THE SCOTTISH CANCER
THERAPY NETWORK
The Scottish Cancer Therapy Network (SCTN) was established in
early 1993 with a 5-year grant of £250 000 per annum from the
Chief Scientist Office and the Clinical Resource and Audit Group,
both of which were part of the then Scottish Office Home and
Health Department The overall aim of the SCTN is to help ensure
that optimal treatment is available throughout Scotland to all
patients with cancer, by providing up-to-date information on clinical
cancer trials, audits of outcome, best current practice for the treat-
ment of cancer and patterns of cancer care throughout Scotland.
Steering committee
A steering committee, relating closely to the already established
Scottish Cancer Coordinating and Advisory Committee (SCCAC)
(Aitken et al, 1994), was established to guide the work of the
Network for the first 5 years. It was chaired by the Chief Scientist;
membership included the Chief Medical Officer for Scotland, five
SCTN grantholders, independent members with special expertise,
and representatives of cancer charities, the Medical Research
Council and the Scottish Breast Screening Programme.
Grantholders
Until recently, the operational aspects of SCTN activities were
guided by five grantholders. The grantholders were chosen to
represent a central office and the catchment areas of the four
academic cancer centres in Scotland, as well as the disciplines of
cancer registration/epidemiology, surgical oncology, clinical
oncology and medical oncology. The grantholders met every 8–12
weeks to monitor progress, debate strategy and priorities, and to
discuss the problems and practicalities of implementation of
SCTN activities.
STRUCTURE AND STAFFING
The central theme of SCTN’s work is that it covers the whole of
Scotland. To this end, a central office and five regional offices
have been established (Figure 1).
The central office is staffed by a coordinator (statistician), and
computing, information and administration staff. Five study co-
ordinators are supported by additional grants to work on specific
projects. The central office is located adjacent to the Scottish
Cancer Registry in the Information & Statistics Division of the
Common Services Agency for the National Health Service (NHS)
in Scotland. This allows SCTN to make effective use of centrally
held information on cancer, including record linkage of mortality
data, which facilitates analysis of survival outcome. The central
office is responsible for co-ordination of projects, computer
support, statistical analysis and dissemination of information.
Personnel and financial services, including administration of the
grant, are provided by the host organization.
Review
In pursuit of excellence for patients with cancer: the
Scottish Cancer Therapy Network model
PL Stroner1, DH Brewster1, JA Dewar2, O Eremin3, A Gould1, GC Howard4 and SB Kaye5
1Information & Statistics Division, National Health Service in Scotland, Room C020, Information and Statistics Division, Trinity Park House, South Trinity Road,
Edinburgh EH5 3SQ, UK; 2Ninewells Hospital and Medical School, Dundee DD1 9SY, UK; 3University of Aberdeen Faculty of Medicine, Aberdeen AB9 2ZD, UK;
4Western General Hospital, Edinburgh EH4 2XU, UK; 5Beatson Oncology Centre, Glasgow G11 6NT, UK
Summary The Scottish Cancer Therapy Network (SCTN) was created against a background of rising concerns about perceived variation in
the quality of care available to patients with cancer. SCTN has established itself as a major organization with the necessary recognition and
infrastructure to provide leadership, support and impetus in the field of clinical guidelines, clinical audit and clinical trials of cancer therapy in
Scotland. Since being formed in 1993, SCTN has been instrumental in the development of three evidence-based, clinical guidelines and in
the completion of detailed, national, retrospective audits of the treatment of five major tumour sites. The infrastructure has been used
successfully to support and encourage trial participation. Challenges for the future are a re-orientation towards prospective audit, widening the
constituency and sense of ownership of SCTN as a resource for practising clinicians, and further increasing recruitment into clinical trials.
Keywords: clinical trials; information services; medical audit; neoplasms; practice guidelines; Scotland
1641
British Journal of Cancer (1999) 79(11/12), 1641–1645
© 1999 Cancer Research Campaign
Article no. bjoc.1998.0262
Received 16 June 1998
Accepted 20 August 1998
Correspondence to: PL StronerThe regional and affiliated offices are staffed by data managers.
They work closely with clinicians, providing administrative
support for participation in clinical trials; they also collect data for
national audits organized by SCTN.
ACHIEVEMENTS
The work of SCTN can be grouped under four main headings:
clinical guidelines; clinical audit; clinical trials and dissemination
of information. Much of SCTN’s work relating to breast cancer,
colorectal cancer and lung cancer has been guided by three multi-
disciplinary, site-specific Focus Groups which were established
with a defined remit (Box 1) under the joint auspices of SCCAC
and the SCTN Steering Committee.
In a departure from this site-specific model, and in recognition
of the importance of palliative care, a Palliative Care Focus Group
was established in 1996. This group has been charged with
tackling many of the ‘generic’ aspects of palliative care that are
common across a range of cancer sites and types. SCTN central
office staff provide the secretariat for each of the Focus Groups.
Clinical guidelines
An early priority for SCTN was the development and, with others,
the subsequent dissemination of multidisciplinary, evidence-based
clinical guidelines relating to the major sites of cancer. Guidelines
have been developed by the site-specific Focus Groups in accor-
dance with the stringent criteria of the Scottish Intercollegiate
Guidelines Network (SIGN) (SIGN, 1995) for colorectal cancer
(SCTN/SIGN, 1997), lung cancer (SCTN/SIGN, 1998a), and
breast cancer (SCTN/SIGN, 1998b). Each set of guidelines
contains a minimum core dataset based on their key, measurable
recommendations and designed to monitor their implementation
nationally.
Clinical audit
SCTN has conducted a series of national, retrospective audits of
breast cancer (Scottish Breast Cancer Focus Group et al, 1996),
colorectal cancer (analysis in progress) and lung cancer (analysis
in progress). In addition, an audit of prostate cancer (Goodman,
1997) has been carried out in collaboration with the Scottish
Urological Oncology Group, and an audit of ovarian cancer
(Junor, 1997) has been carried out in collaboration with colleagues
from the West of Scotland Cancer Surveillance Unit and
Glasgow’s Beatson Oncology Centre.
These audits aim to include all patients in Scotland diagnosed
with the cancer in question during a given period. Patients were
identified from the Scottish Cancer Registry which holds data
believed to be of high quality, both in terms of accuracy (Brewster et
al, 1994) and ascertainment (Brewster et al, 1996, 1997) (Table 1).
Patients were eligible for inclusion in the audits if their cancer
registration diagnosis was valid, if they had not had a previous
malignant neoplasm, and if they were diagnosed and treated in
Scotland during the calendar year of the audit.
As well as providing information on recent practice (Boxes
2–4), the audit databases permit an assessment of the resource
implications of recommendations in clinical guidelines and act as
a baseline against which future changes in clinical practice can be
measured. The data have also been used for the purpose of health
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Figure 1 Location of SCTN offices and staff
Table 1 SCTN national retrospective audits: potential study populations, availability of medical records and status by cancer site
Cancer site (Year(s) of diagnosis) No. of cases registered No. (%) of notes retrieved Status
Breast (1987 & 1993) 5471 5135 (93.8%) Reported
Prostate (1988 & 1993) 2812 2575 (91.6%) Analysis in progress
Colorectal (1993) 3243 3031 (93.5%) Analysis in progress
Ovary (1992, 1993, 1994) 1638 1505 (91.9%) Analysis in progress
Lung (1995) 4297 4049 (94.2%) Analysis in progress
Total 17 461 16 295 (93.3%)
Box 1 Remit of site-specific focus groups
‘…to examine information about the tumour type from the point of
view of aetiology, prevention (including education and screening),
diagnosis, treatment and palliation; adequacy of existing
arrangements and best practice should be considered under each of
these headings. The group should also identify past, current and
future research and audit studies which will inform practice.’service research to establish which patterns or features of care
appear to be advantageous in terms of patient outcomes.
In collaboration with the South East Scotland Lung Cancer
Group, SCTN has undertaken responsibility for coordination,
administration and statistical analysis of a NHS Research and
Development (R&D)-funded prospective audit of lung cancer
management, with particular emphasis on quality of life and
resource use. SCTN are also collaborating with palliative care
colleagues throughout Scotland in a prospective audit of pain
control and prescribing standards.
Clinical trials
SCTN provides administration and coordination for a number of
large multicentre, national and international studies. It works in
a complementary and collaborative fashion to other trials offices
in Scotland and the rest of the UK, and with the European
Organisation for Research and Treatment of Cancer, in Brussels. In
particular, SCTN works closely with, and provides the secretariat
for, the Scottish Cancer Trials Breast Group (SCTBG). The collab-
oration with SCTBG has been successful and the level of recruit-
ment into studies for which the group are responsible exceeds the
expected per capita level of 10% of the UK total (Table 2). SCTN
central office staff also provide statistical advice and administra-
tive support to clinicians involved in the development of clinical
trial protocols. The central office has developed a computerized
clinical trials management system to facilitate randomization, data
entry and form tracking.
SCTN is represented on several national trial steering groups
and has built a reputation as a competent and professional trials
office. Despite recent recognized barriers to clinical research
(Smyth et al, 1994), the network of regional data managers has
succeeded in raising awareness of existing trials and has provided
assistance to clinicians throughout Scotland by facilitating appli-
cations to local and multicentre research ethics committees, trial
entry and data collection. For example, in collaboration with the
SCTBG, SCTN has assisted some cancer units which had not
previously had the resources necessary to enter patients into
clinical trials.
Again in collaboration with the SCTBG, SCTN has been very
successful in attracting funding for trials in breast cancer. It is
important to note that the results of all these trials, whether funded
by charities, research councils or the pharmaceutical industry, will
be in the public domain and are trials of combination therapies or
management approaches rather than of specific drugs.
SCTN regional data managers provide assistance to clinicians
participating in national trials, administered by other trials offices,
such as the AXIS and QUASAR trials in colorectal cancer.
Dissemination of information
Information is disseminated in a variety of ways. A quarterly
SCTN Newsletter is now well-established with a multidisciplinary
circulation in excess of 1000. Four annual reports have been
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Table 2 Recruitment of patients in Scotland into selected breast cancer trials
Trial Scotland Rest of UK % (Scotland of UK total)
ABC Premenopausal 260 854 23
ABC Postmenopausal 248 395 39
Anglo Celtic High Dose 79 268 29
ATAC 193 1302 13
UKDCIS 223 1195 16
BASOII 183 509 26
Total 1186 4523 21
Box 2 National Scottish Breast Cancer Audit 1987 and 1993 – Key
results
The results showed that between 1987 and 1993, there was:
• an increase in the proportion referred to surgeons with a
specialist interest (³ 50 patients/year, or working in teams) from
35% to 57%.
• an increase in the proportion of patients having breast
conservation surgery (40% to 52%) and postoperative
radiotherapy (55% to 75%).
• an increase in the proportion having axillary surgery performed
(79% to 90%)
• an increase in the use of systemic adjuvant therapy, including an
increase in the proportion of premenopausal, node-positive
patients receiving chemotherapy (35% to 75%).
• no increase in the proportion of patients having tumour oestrogen
receptors measured.
• Survival analysis of the 1987 cohort showed that the only non-
treatment factor to influence survival was Health Board of first
treatment. Part of the variation by Health Board seemed to be
explained by the variation in the proportion of patients managed
non-surgically. There was also a suggestion that survival by
Health Board was correlated with the use of systemic adjuvant
therapy in 1987.
• The proportion of women entering clinical trials was 12% in 1987
and remained unchanged in 1993. Patients were more likely to
be entered into a clinical trial if they were referred to an
oncologist or seen by a surgeon with a large case load.
Box 3 National Scottish Prostate Cancer Audit 1988 and 1993 –
Key results
The following were the main important findings of the study:
• In both years, thorough tumour staging was often omitted or
poorly documented.
• Bone scans were used in only 43% of patients for staging
purposes in 1988, increasing to 58% by 1993.
• Use of radical radiotherapy showed marked regional variation;
the use of radical surgery, while still infrequent, increased over
the study period.
• There was a substantial decline in surgical methods of hormonal
manipulation (29% to 12%).
• A surprisingly high use of stilboestrol was seen in 1988 (12%)
with marked regional variation; some use persisted even into
1993 (1%).produced and distributed amongst a wide range of disciplines. The
results of the breast cancer audit have been published in a special
report (Scottish Breast Cancer Focus Group et al, 1996) and publi-
cations are beginning to appear in peer-reviewed journals
(Twelves et al, 1998a, 1998b). During their development, the clin-
ical guidelines were presented and discussed at open meetings
attended by a wide range of delegates at the Royal College of
Physicians of Edinburgh.
The rapid changes in information technology and the exponen-
tial growth of the Internet present new opportunities for the
dissemination of information to a wider audience. SCTN is
currently developing a website in collaboration with their host
organization.
FUTURE PLANS
Against the background of a major re-organization of cancer
services, following the Calman/Hine Report (Department of
Health Expert Advisory Group on Cancer, 1995) and related
reports in Scotland (SCCAC, 1996, 1997), SCTN faces a number
of challenges in the future. Firstly, credible, contemporary data
will be needed to monitor the impact of the re-organization of
cancer services, and the dissemination and implementation of
evidence-based clinical guidelines. Thus, it is necessary for SCTN
to shift its emphasis away from retrospective audit towards the
facilitation and support of local, but (with the support of the
Scottish Cancer Registry) population-based, prospective audit.
The second, related challenge, is for SCTN to extend its network
further as a facilitating organization, particularly involving cancer
units. Finally, it is important for SCTN to increase recruitment into
clinical trials involving patients with lung and colorectal cancer, to
match the success in breast cancer. This will be a new focus of
attention for the Colorectal and Lung Cancer Focus Groups.
Following a review in June 1997, funding for SCTN has been
secured for a further 3 years, in the first instance. The management
arrangements for SCTN have altered to reflect changes in the struc-
ture of cancer committees within the Scottish Office Department of
Health. SCCAC and the SCTN Steering Committee have ceased to
exist and their functions have, in effect, been taken over by a newly
formed Cancer Executive Group which will oversee the activities
of SCTN and will report, through a newly formed Scottish Cancer
Group, to the Chief Medical Officer for Scotland.
CONCLUSION
Since its formation in 1993, SCTN has established itself as a major
organization with the necessary recognition and infrastructure to
provide leadership, support and impetus in the field of clinical
guidelines, clinical audit and clinical trials of cancer therapy in
Scotland. Challenges for the future are a re-orientation towards
prospective audit, widening the constituency and sense of owner-
ship of SCTN as a resource for practising clinicians, and
increasing further recruitment into clinical trials.
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